Heparanase – Pipeline Review, H2 2020
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 188.8.131.52) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Heparanase – Pipeline Review, H2 2020, outlays comprehensive information on the Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 184.108.40.206) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 220.127.116.11) – Heparanase is an endoglycosidase which cleaves heparan sulfate (HS) and hence participates in degradation and remodeling of the extracellular matrix (ECM). Heparanase is preferentially expressed in human tumors and its over-expression in tumor cells. The enzyme also releases angiogenic factors from the ECM and thereby induces an angiogenic response. Heparanase exhibits also non-enzymatic activities, independent of its involvement in ECM degradation. Among these, are the enhancement of Akt signaling, stimulation of PI3K- and p38-dependent endothelial cell migration, and up regulation of VEGF, all contributing to its potent pro-angiogenic activity. Inhibiting the enzyme is beneficial in treatment of cancer.
The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Ophthalmology and Immunology which include indications Coronavirus Disease 2019 (COVID-19), Retinopathy, Breast Cancer, Dry (Atrophic) Macular Degeneration, Head And Neck Cancer, Inflammation, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Pancreatic Cancer, Refractory Multiple Myeloma, Solid Tumor and Wet (Neovascular / Exudative) Macular Degeneration.
Furthermore, this report also reviews key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 18.104.22.168) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The report provides a snapshot of the global therapeutic landscape for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 22.214.171.124)
– The report reviews Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 126.96.36.199) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 188.8.131.52) targeted therapeutics and enlists all their major and minor projects
– The report assesses Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 184.108.40.206) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 220.127.116.11) targeted therapeutics
Reasons to Buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 18.104.22.168)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 22.214.171.124) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Beta Therapeutics Pty Ltd
Leadiant Biosciences Inc
Momenta Pharmaceuticals Inc
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Zucero Therapeutics Ltd
For queries regarding this report: https://www.researchbymarkets.com/sample-request/645874